Axitinib vs placebo in patients at high risk of recurrent renal cell carcinoma (RCC): ATLAS trial results

被引：0

作者：

Gross-Goupil, M. ^{[1
]}

Kwon, T. G. ^{[2
]}

Eto, M. ^{[3
]}

Ye, D. ^{[4
]}

Miyake, H. ^{[5
]}

Seo, S. I. ^{[6
]}

Byun, S. S. ^{[7
]}

Lee, J. L. ^{[8
]}

Master, V. ^{[9
]}

Jin, J. ^{[10
]}

Debenedetto, R. ^{[11
]}

Linke, R. ^{[12
]}

Casey, M. ^{[13
]}

Rosbrook, B. ^{[14
]}

Frean, M. J. Lechuga ^{[15
]}

Valota, O. ^{[16
]}

Grande, E. ^{[17
]}

Quinn, D. I. ^{[18
]}

机构：

[1] Hop St Andre, Dept Oncol, CHU Bordeaux, Bordeaux, France

[2] Kyungpook Natl Univ, Sch Med, Daegu, South Korea

[3] Kyushu Univ, Dept Clin Med, Fukuoka, Fukuoka, Japan

[4] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[5] Hamamatsu Univ, Sch Med, Hamamatsu, Shizuoka, Japan

[6] Sungkyunkwan Univ, Dept Urol, Seoul, South Korea

[7] Seoul Natl Univ, Bundang Hosp, Seongnam, South Korea

[8] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[9] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA

[10] Peking Univ, Dept Urol, Hosp 1, Beijing, Peoples R China

[11] SFJ Pharmaceut, Clin Dev & Med Affairs, Pleasanton, CA USA

[12] SFJ Pharmaceut Inc, Clin Dev & Med Affairs, Pleasanton, CA USA

[13] Pfizer Inc, Dept Oncol, Collegeville, PA USA

[14] Pfizer Inc, Translat Oncol, La Jolla, CA USA

[15] Pfizer Italia Srl, Dept Oncol, Milan, Italy

[16] Pfizer Srl, Dept Oncol, Milan, Italy

[17] MD Anderson Canc Ctr Ctr Espana, Dept Med Oncol, Madrid, Spain

[18] Univ Southern Calif, Translat & Clin Sci Program, Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA USA

来源：

ANNALS OF ONCOLOGY | 2018年 / 29卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

863O

引用

页码：303 / 303

页数：1

共 50 条

[21] The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC)
Voss, M. H.
Plimack, E.
Rini, B.
Bhatt, R. S.
Alter, R.
Beck, J. T.
Mutyaba, M.
Pappas, K.
Wilson, D.
Zhang, X.
Sun, J.
Glasser, C.
Sherman, M. L.
Pandya, S. S.
Atkins, M. B.
BJU INTERNATIONAL, 2015, 116 : 22 - 23
[22] The DART Study: A phase 2 randomized double-blind study of dalantercept plus axitinib versus placebo plus axitinib in advanced clear cell renal cell carcinoma (RCC).
Voss, Martin Henner
Plimack, Elizabeth R.
Rini, Brian I.
Atkins, Michael B.
Alter, Robert
Bhatt, Rupal Satish
Beck, J. Thaddeus
Mutyaba, Musa
Pappas, Kristen M.
Wilson, Dawn
Zhang, Xiaosha
Sherman, Matthew L.
Pandya, Shuchi Sumant
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[23] Phase I trial of a PSMA DNA vaccine for patients(pts) with good risk renal cell carcinoma(RCC)
Slovin, S. F.
Motzer, R. J.
Jefferson, M.
Gregor, P.
Wolchok, J. D.
Czarny, M.
Curley, T.
Delacruz, A.
Scher, H. I.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[24] The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC).
Voss, Martin Henner
Plimack, Elizabeth R.
Rini, Brian I.
Atkins, Michael B.
Alter, Robert
Bhatt, Rupal Satish
Beck, J. Thaddeus
Mutyaba, Musa
Pappas, Kristen M.
Wilson, Dawn
Zhang, Xiaosha
Sherman, Matthew L.
Pandya, Shuchi Sumant
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[25] AXITINIB IN TREATMENT OF METASTATIC CHROMOPHOBE RENAL CELL CARCINOMA (MET CH RCC)-ACASE REPORT
Nadiminti, K.
Vaena, D.
Nadiminti, K.
Vaena, D.
JOURNAL OF INVESTIGATIVE MEDICINE, 2014, 62 (04) : 735 - 736
[26] The DART Study: Part 1 results from the dalantercept plus axitinib dose escalation and expansion cohorts in patients with advanced renal cell carcinoma (RCC)
Voss, M. H.
Plimack, E.
Rini, B.
Alter, R.
Bhatt, R. S.
Beck, J. T.
Mutyaba, M.
Pappas, K.
Wilson, D.
Zhang, X.
Sun, J.
Glasser, C.
Sherman, M. L.
Pandya, S. S.
Atkins, M. B.
BJU INTERNATIONAL, 2015, 116 : 22 - 22
[27] A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
Tsimafeyeu, Ilya
Borisov, Pavel
Abdelgafur, Ahmed
Leonenkov, Roman
Novikova, Olga
Guseva, Irina
Demchenkova, Marina
Mikhailova, Nadezhda
Semenov, Andrey
Yurmazov, Zakhar
Sivunova, Irina
Ramazanova, Madina
Gamayunov, Sergey
Kosov, Dmitry
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
[28] Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC)
Tannir, B.
Hardikar, S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[29] Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).
Bex, Axel
Abu-Ghanem, Yasmin
Van Thienen, Johannes V.
Graafland, Niels
Lagerveld, Brunolf
Zondervan, Patricia
Beerlage, Harrie
van Moorselaar, Jeroen
Kockx, Mark
Van Dam, Pieter-Jan
Szabados, Bernadett
Blank, Christian U.
Powles, Thomas
Haanen, John B. A. G.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[30] Updated results of the phase 3 AXIS trial: Axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
Escudier, B.
Rini, B., I
Hutson, T. E.
Gore, M.
Oudard, S.
Tarazi, J.
Rosbrook, B.
Williams, J. A.
Kim, S.
Motzer, R. J.
EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E81 - U450

← 1 2 3 4 5 →